You are using an older browser version. Please use a supported version for the best MSN experience.

Gilead says remdesivir cuts death risk

Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients. Fred Katayama reports.

UP NEXT

UP NEXT

CNBC

image beaconimage beaconimage beacon